Aurinia Pharmaceuticals (AUPH) COO Ryan Cole becomes SEC Form 3 insider

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. disclosed that Chief Operating Officer Ryan Cole filed an initial statement of beneficial ownership on Form 3. This filing formally registers him as a reporting person for the company’s equity under securities regulations and establishes the baseline for any future insider transaction reports.

Key Terms

Form 3, beneficial ownership, reporting person, Chief Operating Officer

4 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"filed an initial statement of beneficial ownership on Form 3"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"registers him as a reporting person for the company’s equity"

Chief Operating Officer financial

"Ryan Cole, Chief Operating Officer of Aurinia Pharmaceuticals Inc."

A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cole Ryan

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Ryan Cole	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Aurinia Pharmaceuticals (AUPH) Form 3 for Ryan Cole mean?

The Form 3 shows that Ryan Cole, Aurinia’s Chief Operating Officer, has become a reporting person for the company’s securities. It serves as his initial beneficial ownership statement, forming the basis for future Form 4 or Form 5 insider transaction reports.

Who is the reporting person on Aurinia Pharmaceuticals (AUPH) this Form 3?

The reporting person is Ryan Cole, Chief Operating Officer of Aurinia Pharmaceuticals Inc. As an officer, he must report his beneficial ownership and future changes in his holdings through SEC forms such as Form 3, Form 4, and Form 5.

Does the Aurinia Pharmaceuticals (AUPH) Form 3 show any insider trades?

This Form 3 is an initial beneficial ownership statement and does not report any specific buy or sell transactions. Actual insider trades, such as purchases or sales of shares, would appear later on Forms 4 or 5 once they occur.

Why is a Form 3 filing important for Aurinia Pharmaceuticals (AUPH) investors?

Form 3 identifies insiders like the Chief Operating Officer who must publicly report their holdings. It enhances transparency around management’s equity interests, helping investors track future insider transactions and potential alignment between leadership and shareholder value.

Is Ryan Cole a major shareholder of Aurinia Pharmaceuticals (AUPH) based on this Form 3?

The metadata indicates Ryan Cole is not a ten percent owner. He files as Chief Operating Officer, which triggers reporting obligations as a company officer, rather than as a large equity holder with a stake above ten percent of Aurinia’s outstanding shares.